Potentials for the use of aflibercept in the treatment of patients with metastatic colorectal cancer
- Authors: Vladimirova L.Y.1, Abramova N.A.1, Popova I.L1, Storozhakova A.E1, Novoselova K.A1, Tikhanovskaya N.M1, Ryadinskaya L.A1, Lyanova A.A1, Myagkova V.S1, Teplyakova M.A1, Kabanov S.N1, Kalabanova E.A1, Samaneva N.Y.1, Tishina A.V1, Strakhova L.K1, Yezhova M.O1
-
Affiliations:
- National Medical Research Centre for Oncology
- Issue: Vol 27, No 11 (2020)
- Pages: 36-41
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312872
- DOI: https://doi.org/10.18565/pharmateca.2020.11.36-41
- ID: 312872
Cite item
Abstract
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
L. Yu Vladimirova
National Medical Research Centre for OncologyRostov-on-Don, Russia
Nataliya A. Abramova
National Medical Research Centre for Oncology
Email: pylulkin@mail.ru
Cand. Sci. (Med.), Senior Researcher at the Department of Antitumor Drug Treatment 63, 14 line, Rostov-on-Don 344037, Russian Federation
I. L Popova
National Medical Research Centre for OncologyRostov-on-Don, Russia
A. E Storozhakova
National Medical Research Centre for OncologyRostov-on-Don, Russia
K. A Novoselova
National Medical Research Centre for OncologyRostov-on-Don, Russia
N. M Tikhanovskaya
National Medical Research Centre for OncologyRostov-on-Don, Russia
L. A Ryadinskaya
National Medical Research Centre for OncologyRostov-on-Don, Russia
A. A Lyanova
National Medical Research Centre for OncologyRostov-on-Don, Russia
V. S Myagkova
National Medical Research Centre for OncologyRostov-on-Don, Russia
M. A Teplyakova
National Medical Research Centre for OncologyRostov-on-Don, Russia
S. N Kabanov
National Medical Research Centre for OncologyRostov-on-Don, Russia
E. A Kalabanova
National Medical Research Centre for OncologyRostov-on-Don, Russia
N. Yu Samaneva
National Medical Research Centre for OncologyRostov-on-Don, Russia
A. V Tishina
National Medical Research Centre for OncologyRostov-on-Don, Russia
L. K Strakhova
National Medical Research Centre for OncologyRostov-on-Don, Russia
M. O Yezhova
National Medical Research Centre for OncologyRostov-on-Don, Russia
References
- Chiron M., Bagley R.G., Pollard J, et al. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. Mol Cancer Ther. 2014;13(6):1636-44. Do: 10.1158/1535-7163.MCT-13-0753.
- Van Cutsem E., Tabernero J., Lakomy R., et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012;30(28):3499-506. doi: 10.1200/JCO.2012.42.8201.
- Федянин М.Ю., Владимирова Л.Ю., Чубенко В.А. и др. Оценка токсичности и эффективности Vladimirova L.Yu., Abramova N.A. - study concept and design. Abramova N.A., Popova I.L., Tikhanovskaya N.M.,терапии комбинацией FOLFIRI и афлиберцепта при метастатическом раке толстой кишки в РФ: первые результаты многоцентрового ретроспективного исследования. Злокачественные опухоли Российское общество клинической онкологии. 2019;9(2):53-63.
- Pastorino A., Di Bartolomeo M., Maiello E., et al. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clin Colorectal Cancer. 2018;17(3):e457-e470. Doi: 10.1016/j. clcc.2018.03.002.
- Montes A.F., Lago N.M., Rua M.C., et al. Efficacy and safety of FOLFIRI/aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Medicine. 2019;8(3):882-89. doi: 10.1002/cam4.1903.
- Hofheinz R, Thaler J, Von Moos R, et al. Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study. J Clin Oncol. 2016;34(4_suppl):681-81. Doi: 10.1093/ annonc/mdz156.025.
- Hofheinz R.D, Derigs H., Piringer G, et al. Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI: Efficacy according to age group 565 and >65 years. Ann Oncol. 2018;29(suppl_8). doi: 10.1093/annonc/ mdy281.121.
- Ivanova J.I., Saverno K.R., Sung J, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017;34 (12):193. doi: 10.1007/s12032-017-1049-4.
Supplementary files
![](/img/style/loading.gif)